-+ 0.00%
-+ 0.00%
-+ 0.00%

CStone plans first wave of global Phase III trials for CS2009 by end-2026

PUBT·08/31/2026 12:23:58
Listen to the news
CStone plans first wave of global Phase III trials for CS2009 by end-2026
  • CStone highlighted stronger mid-stage clinical results for lead cancer drug CS2009, supporting plans to start global Phase III registrational trials by end-2026.
  • Earlier findings were presented at ASCO in May 2026; more mature data are scheduled for rapid oral presentations at ESMO 2026 in October.
  • Updated follow-up continued to show favorable safety, with no new safety signals, alongside deepening anti-tumor activity across several tumor types.
  • Management expects to align with the FDA and China’s CDE on the Phase III protocol in Q4 2026, a key step toward late-stage execution.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CStone Pharmaceuticals published the original content used to generate this news brief via CNW (Ref. ID: 202608310822CANADANWCANADAPR_C4096) on August 31, 2026, and is solely responsible for the information contained therein.